Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
← catalyst calendarNCT05636618 · readout in 1,195 d
Sponsored by Perspective Therapeutics (industry) · CATX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
300estimated
Sites
19
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-27 | actual | When the study began enrolling |
| Primary completion | 2029-11-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-26 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neuroendocrine Tumors Unresectable
- Neuroendocrine Tumor Metastatic
- Gastroenteropancreatic Neuroendocrine Tumor
- Bronchial Neuroendocrine Tumor
- Paraganglioma
- Pheochromocytoma
- Meningioma
Interventions
- Drug: [203Pb]VMT-α-NET
- Drug: [212Pb]VMT-α-NET
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT-α-NET
measured Incidence and severity of DLTs during the first 42 days of study treatment will be assessed.
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 in subjects with NETs
measured Up to week 96
ORR per Response Assessment in Neuro-Oncology (RANO) meningioma criteria in subjects with meningioma
measured Up to week 96
Number of subjects with adverse events (AEs)
measured Until the end of study (3 years after end-of-study visit)
Permalink · CATX's whole pipeline · Catalyst calendar · Every registered study · What changed